ACTRN12613000532707已完成4 期
Pilot Randomized Control Trial of Meropenem vs. Piperacillin-Tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia Coli and Klebsiella spp.
Australasian Society of Infectious Diseases Clinical Research Network0 个研究点目标入组 100 人开始时间: 2013年5月13日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Bloodstream infection with Escherichia coli or Klebsiella spp., as defined by at least one positive blood culture from a peripheral blood draw.
- •2. Bacteria confirmed as ceftriaxone non-susceptible, Piperacillin-Tazobactam susceptible and Meropenem susceptible by use of EUCAST definitions (www.eucast.org).
- •3. No more than 72 hours since the first positive blood culture was collected for this infection.
- •4. Patient or their ethics committee approved proxy able to give written informed consent.
排除标准
- •1. Patient not expected to survive more than 4 days.
- •2. Patient allergic to a penicillin or a carbapenem.
- •3. Patient with significant polymicrobial bacteraemia (that is, a Gram positive skin containment in one set of blood cultures is not regarded as significant polymicrobial bacteraemia).
- •4. Treatment is not with the intent to cure the infection (that is, palliative care is an exclusion).
研究者
相似试验
终止
4 期
Randomized Control Trial of Meropenem versus Piperacillin-Tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia Coli and Klebsiella species.ACTRN12615000403538Australasian Society of Infectious Diseases Clinical Research Network454
招募中
4 期
Pilot randomised controlled trial of meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections.Participants who have had a bloodstream infection with a specific gram negative bacteria, as defined by at least one positive blood culture, where the isolate is confirmed to be a likely AmpC-producer by resistance to Ampicillin, Amoxicillin/clavulanate and 1st generation cephalosporins (e.g. cephazolin). The isolate should also remain susceptible to piperacillin/tazobactam and meropenem.Infection - Studies of infection and infectious agentsACTRN12614001211651The University of Queensland Centre for Clinical Research100
终止
4 期
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.Bloodstream InfectionsNCT02176122The University of Queensland391
招募中
Unknown
Randomised Controlled Trial of Meropenem versus Cefmetazole for definitive treatment of bloodstream infections due to ESBL- producing Escherichia coliJPRN-UMIN000049016ational Center for Global Health and Medicine, Disease Control and Prevention Center169
已完成
不适用
Randomized trial of doripenem or meropenem in the treatment of febrile neutropeniapatients with febrile neutropeniaJPRN-UMIN000006944Tokyo Women's Medical University100